Hyperlipoproteinemia
Conditions
Brief summary
The purpose of this study is to compare the lipid lowering effects and clinical safety of a natural hypolipidemic compound, coenzyme A capsule with a marketed drug, fenofibrate, in Chinese patients with moderate dyslipidemia.
Detailed description
Although lowering cholesterol and low-density lipoprotein-cholesterol (LDL-C) is the mainstay of medical therapy for cardiovascular event prevention, evidence from clinical trials supports a role for elevated triglyceride (TG) and low high-density lipoprotein cholesterol (HDL-C) concentrations in the residual cardiovascular risk on statin treatment. Fenofibrate is the most commonly used agent to control hypertriglyceridemia as monotherapy or combining with statin, which lowers TG and raises HDL-C through multifaceted mechanism by PPARα activation. However, safety of coadministration of statin with fenofibrate has been a great concern, especially drug-induced hepatotoxicity when they are combined used. Coenzyme A (CoA) functions as an acyl group carrier and assists in transferring fatty acids from the cytoplasm to mitochondria. It is also involved in the oxidation and catabolism of fatty acids. Animal studies have proved its lipid-lowering effects. In a previous multicenter study we conducted in 2008, it was found that oral CoA 400U/d effectively lowered serum TG levels in hypertriglyceridemia patients without increasing adverse effects when compared with placebo. So, the present study was performed to further investigate the lipid-lowing effects and safety of CoA capsule by comparing with fenofibrate.
Interventions
DRUGCoenzyme A
Coenzyme A 400mg per day
Fenofibrate 200mg per day
Sponsors
Zhejiang University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* TG 2.3～6.5mmol/l * 18-75 years of age
Exclusion criteria
* TC \>7.0 mmol/l; * Body Mass Index \> 30 kg/m2 * drug induced secondary hypercholesterolemia (such as dibenzothiazine, contraceptive agent or adrenal cortex hormone) * pregnancy * acute coronary syndrome, acute myocardial infarction or undergone a revascularization procedure within 6 months * acute liver disease or hepatic dysfunction, as determined by levels of alanine aminotransferase (ALT) or aspartate aminotransferase levels (AST) more than 3-fold the upper normal limit * nephrotic syndrome or serum creatinine (Cr) (≥179 µmol/L) and creatine •phosphokinase (CK) more than 3-fold the upper normal limit * primary hypothyroidism * psychiatric patients * poorly controlled hypertension, as indicated by a Systolic Blood Pressure \>180 mmHg or Diastolic Blood Pressure \>110 mmHg * Type I diabetes mellitus（DM）, poorly controlled Type II DM (BS\>11.0 mmol/L ) or Type II DM with LDL-C \>2.6 mmol/L. * using immunosuppressive drugs, prohibited medication or other lipid-lowing drugs
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| serum triglyceride level | 10 months | The primary efficacy variable was the percentage change in serum lipid level from baseline to 4 and 8 weeks of treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| serum total cholesterol level | 10 months | change from baseline to 4 and 8 weeks of treatment in serum total cholesterol level. |
| low-density lipoprotein cholesterol level | 10 months | change from baseline to 4 and 8 weeks of treatment in serum low-density lipoprotein cholesterol level. |
| serum high-density lipoprotein cholesterol level | 10 months | change from baseline to 4 and 8 weeks of treatment in serum high-density lipoprotein cholesterol level. |
Countries
China
Outcome results
None listed